Quintiles Automates Global Phase I Clinic Operations With TrialOne
FORT LAUDERDALE, FL-- OmniComm Systems, Inc. (
After a thorough evaluation of commercially available Phase I software, Quintiles' Early Clinical Development (ECD) selected OmniComm's TrialOne software to replace its legacy Phase I Clinical Trial Development System (PICTS). This was part of a company-wide initiative to standardize Quintiles global Phase I clinics on a best-in-class technology that provides increased performance, functionality and better business decision making tools. TrialOne will provide the ECD clinics, in the UK and US, with a competitive edge in the marketplace, as well as make ECD operations more efficient, leading to higher quality trials, easier access to data, better integration with Infosario® (Quintile's analytics platform), and enhanced control of patient safety.
TrialOne's architecture will also allow for easier integration with Infosario's powerful analytics platform. Client-specific data libraries can be easily developed and segregated for quick study start-up to clients' data specifications. As ECD transitions to more patient studies, data capture can occur from any location that has internet access, allowing ECD to utilize hospital and external site settings without resorting to paper case report forms. Finally, a GMP compliant pharmacy labeling package will allow Quintiles's clinics to produce investigational product labels in one system.
"OmniComm is delighted to add Quintiles to our growing list of TrialOne clients," stated Randy Smith, OmniComm's CTO and TrialOne Group Executive Sponsor. "TrialOne's comprehensive functionality and global deployment will allow Quintiles to realize operational efficiencies which will translate into superior service and faster, industry data for Quintiles and their clients."
About OmniComm Systems
OmniComm Systems is a leading strategic software solutions provider to the life sciences industry. OmniComm Systems is dedicated to helping the world's pharmaceutical; biotechnology; contract research organizations; diagnostic and device firms; and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from over 4,000 clinical trials. For more information, visit www.omnicomm.com.
Safe Harbor Disclaimer
Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
OmniComm, TrialMaster, TrialOne, and Promasys are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.